# Neurodegenerative Disease Market

> Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions), By Route of Administration (Oral, Injectable, Intravenous, Transdermal) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 7.5%
- **2025:** USD 54.93 Billion
- **2035:** USD 112.72 Billion
- **Key Players:** Biogen, Eisai, Eli Lilly, AbbVie, Roche / Genentech, Novartis, Teva, Lundbeck

**Report ID:** MRFR/LS/17671-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** September 10, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218

---

## Market Summary

As per MRFR analysis, the Neurodegenerative Disease Market size was valued at USD 68.27 Billion in 2024. The market is projected to grow from USD 73.46 Billion in 2025 to USD 152.85 Billion by 2035, exhibiting a CAGR of 7% during the forecast period 2025–2035. North America dominated the Neurodegenerative Disease Market with the largest revenue share of 44.97% in 2024.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Population aging and rising prevalence | 1.9 | Global | Long-term (≥4 yr) | [7][8] |
| Approval and uptake of amyloid-directed antibodies | 1.6 | North America, Japan | Short-term (≤2 yr) | [1][3] |
| Blood-based diagnostic adoption | 1.2 | Global | Medium-term (2–4 yr) | [6] |
| Public research funding and dementia plans | 1.0 | North America, Europe | Long-term (≥4 yr) | [2][9] |
| Advanced-stage Parkinson's delivery innovation | 0.8 | North America, Europe | Medium-term (2–4 yr) | [5][10] |
| Genetically defined subtype targeting | 0.7 | Global | Long-term (≥4 yr) | [11] |
| Asia-Pacific screening mandates | 0.6 | Asia-Pacific | Medium-term (2–4 yr) | [12] |

### Population Aging and Prevalence Load

Demographics do most of the work here. The Global Burden of Disease neurological analysis published in Lancet Neurology in 2024 attributed more than 11 million disability-adjusted life years to Alzheimer's disease and other dementias, with the over-65 cohort carrying nearly all of it [[7]](https://thelancet.com). Japan already runs above 29% of its population past 65; Italy and Germany follow. Because incidence roughly doubles every five years after age 65, a decade of demographic drift alone adds patients faster than any pricing action removes revenue. This is the floor under the neurodegenerative disease market, and it does not depend on any single molecule succeeding.

### Disease-Modifying Antibody Uptake

Regulatory momentum turned decisively in 2023. Lecanemab converted from accelerated to traditional approval on 6 July 2023, and donanemab followed on 2 July 2024 [[1]](https://fda.gov)[[3]](https://alzint.org). Both carry list prices above USD 26,000 per year and require MRI monitoring for amyloid-related imaging abnormalities, which concentrates prescribing in specialist centers. Uptake has been slower than launch models assumed — infusion capacity, not demand, is the constraint. The August 2025 clearance of a once-weekly subcutaneous maintenance formulation directly attacks that bottleneck by moving patients out of infusion chairs after the induction period [[4]](https://practicalneurology.com).

### Diagnostic Reclassification

Diagnosis was the hidden rate limiter for a decade. Amyloid PET costs USD 4,000–7,000 and sits in a few hundred US facilities; cerebrospinal fluid sampling deters patients. Clearance of the Lumipulse plasma pTau217/β-amyloid 1–42 ratio test in 2025 for adults aged 50 and over with cognitive symptoms changed the funnel economics outright [[6]](https://fda.gov). A blood draw priced in the low hundreds allows primary care to triage before referral, which expands the treatable population without expanding specialist headcount. Diagnostics revenue is small relative to therapeutics, but it gates everything downstream.

### Public Funding and National Dementia Plans

Government commitment has proved durable across administrations. US federal spending on Alzheimer's and related dementia research through the National Institutes of Health sits near USD 3.8 billion annually, up roughly nine-fold since 2015 [[2]](https://nia.nih.gov). The World Health Organization's global dementia action plan pushed member states toward costed national strategies, and more than 40 countries have adopted one [[9]](https://who.int). Public money underwrites the long, expensive natural-history and biomarker cohorts that private sponsors will not fund alone.

## Restraints

## Restraints Impact Analysis

Restraint weightings are directional estimates of drag on growth momentum. They are analyst judgments, not subtractive inputs to the headline CAGR.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Generic erosion in symptomatic classes | 1.4 | Global | Short-term (≤2 yr) | [13] |
| Payer restriction and HTA rejection | 1.1 | Europe, Asia-Pacific | Medium-term (2–4 yr) | [14] |
| Infusion and MRI infrastructure limits | 0.9 | Global | Short-term (≤2 yr) | [4] |
| High clinical trial failure rates | 0.7 | Global | Long-term (≥4 yr) | [15] |
| Diagnostic delay in low-resource settings | 0.5 | South America, MEA | Long-term (≥4 yr) | [8] |

###  

### Payer Restriction and Divergent HTA Outcomes

The transatlantic split is stark. European regulators took a far more restrictive line on amyloid antibodies than the FDA, narrowing eligible populations and, in donanemab's case, issuing an unfavourable opinion that drew public criticism from patient organizations [[14]](https://ema.europa.eu). Even where marketing authorization exists, national HTA bodies in England, France and Germany apply separate value assessments that can delay funded access by two years. Companies now model Europe as a slow, restricted market rather than a second US.

### Clinical Attrition

Failure remains the industry's dominant expense. Analyses of central nervous system development cite success rates from Phase I to approval below 8%, among the lowest of any therapeutic area, with Alzheimer's historically worse [[15]](https://alz.org). Aducanumab's withdrawal after a terminated confirmatory program is a reminder that approval is not the finish line. High attrition raises the cost of capital for smaller sponsors and pushes risk toward partnered structures.

## Opportunities

## Neurodegenerative Disease Market Opportunities

### Prodromal and Preventive Treatment

The largest untapped pool sits upstream of symptoms. Secondary-prevention trials enrolling amyloid-positive but cognitively normal adults would, if positive, multiply the eligible population several times over. Blood-based screening makes such enrollment economically feasible for the first time.

### Emerging-Market Access Models

India, Brazil, Indonesia and Egypt face rapidly aging populations without specialist neurology density. Tiered pricing paired with task-shifted screening delivered by trained primary-care nurses opens volume markets that premium infusion models cannot reach. Latin America and Africa together represent under 10% of current revenue but a far larger share of undiagnosed prevalence.

### Real-World Evidence and Registry Monetization

Registry-conditioned reimbursement created a structural data asset. Longitudinal outcome data on antibody-treated patients has value to payers pricing risk-sharing agreements, to sponsors designing label expansions, and to health systems planning capacity. Companies that build the analytics layer, rather than merely submit to it, capture a recurring revenue line independent of unit sales.

### Genetically Defined Subtypes

SOD1-ALS, LRRK2 and GBA1 Parkinson's, and Huntington's each offer a defined molecular target and a screenable population. Precision approaches shorten trials, support premium pricing, and face less competition from generics.

### Home-Delivered Maintenance

Subcutaneous and transdermal delivery moves chronic dosing out of hospital settings. This is where the fastest route-of-administration growth sits, and it changes the buyer from a hospital pharmacy to a specialty distributor.

## Future Outlook

## Neurodegenerative Disease Market Future Outlook

### Machine Learning in Target Discovery

Computational platforms are compressing the early phase of drug discovery. Sponsors now routinely screen genetic association data against protein structure predictions before committing to wet-lab validation, shortening target identification from years to months. The practical effect on the neurodegenerative disease market is a wider set of shots on goal in a field where attrition above 90% has historically limited how many mechanisms get tested at all [[15]](https://alz.org).

### Decentralized Care Economics

Delivery is migrating out of the hospital. Subcutaneous maintenance dosing, wearable [infusion pumps](https://www.marketresearchfuture.com/reports/infusion-pumps-market-1509) for advanced Parkinson's, and remote MRI scheduling shift cost from facility to home [[4]](https://practicalneurology.com)[[5]](https://news.abbvie.com). Health systems favor this because infusion suite time is their scarcest resource; manufacturers favor it because it removes a capacity ceiling on volume.

### Biosimilar Entry and Second-Wave Pricing

First-generation antibodies face composition-of-matter expiry in the early 2030s. Expect pricing pressure to arrive before biosimilars do, as second-wave entrants with better safety profiles or shorter titration compete on total cost of care rather than list price. Companies with subcutaneous and every-four-week formats will defend share more effectively than those tied to biweekly infusion.

### Prevention Reframing

If any secondary-prevention program reads out positive before 2032, the neurodegenerative disease market changes character entirely — from a specialist treatment category to a screened primary-care one. That single binary outcome carries more forecast variance than every other assumption in this report combined.

## Segment Insights

## Neurodegenerative Disease Market Segmentation

### By Indication

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Alzheimer's Disease | 39.2% share (2025) | Antibody uptake and diagnostic expansion |
| Parkinson's Disease | USD 13.62 billion (2025) | Advanced-stage delivery innovation |
| Multiple Sclerosis | 16.5% share (2025) | Established high-efficacy therapy base |
| Amyotrophic Lateral Sclerosis | 10.0% CAGR (2026–2035) | Genetically targeted antisense agents |
| Huntington's Disease | 5.1% share (2025) | Gene therapy pipeline anticipation |
| Other Indications | USD 4.12 billion (2025) | Rare ataxias and atypical parkinsonism |

Alzheimer's dominates the neurodegenerative disease market because it combines the largest patient pool with the only recently approved premium therapies. The economics remain awkward — high price, modest benefit, heavy monitoring — but the category now has a value anchor it lacked before 2023. Parkinson's is the more interesting near-term story. Its innovation is happening in delivery rather than mechanism: continuous subcutaneous levodopa infusion and wearable apomorphine pumps converted a generic molecule into a premium-priced device-drug combination [[5]](https://news.abbvie.com)[[10]](https://supernus.com).

### By Drug Class

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Cholinesterase Inhibitors | 26.3% share (2025) | Universal first-line symptomatic use |
| Dopaminergic Agents | USD 11.75 billion (2025) | Parkinson's standard of care |
| Immunotherapies and Monoclonal Antibodies | 19.6% share (2025) | Amyloid clearance approvals |
| NMDA Antagonists | 14.7% share (2025) | Moderate-to-severe dementia management |
| Other Symptomatic Agents | USD 7.25 billion (2025) | Agitation and sleep comorbidity |
| Gene and Cell Therapies | 9.9% CAGR (2026–2035) | Monogenic disease pipelines |

### By Molecule Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Small-Molecule Drugs | 56.9% share (2025) | Oral convenience and generic pricing |
| Biologics and Monoclonal Antibodies | USD 17.47 billion (2025) | Disease-modifying therapies in Alzheimer's |
| RNA-Based Therapeutics | 9.8% CAGR (2026–2035) | Antisense success in SOD1-ALS |
| Cell and Gene Therapies | 4.9% share (2025) | One-time administration value proposition |

### By Route of Administration

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Oral | 72.3% share (2025) | Symptomatic generic dominance |
| Injectable / Parenteral | USD 12.03 billion (2025) | Antibody induction dosing |
| Transdermal / Intranasal | 10.6% CAGR (2026–2035) | Swallowing difficulty in late-stage disease |

### By Distribution Channel

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 50.7% share (2025) | Infusion administration and MRI co-location |
| Retail Pharmacies | USD 20.21 billion (2025) | Chronic oral maintenance refills |
| Online Pharmacies | 10.8% CAGR (2026–2035) | Home delivery for caregiver convenience |

Hospital pharmacies lead because the highest-value products require supervised administration and imaging surveillance. That grip loosens as subcutaneous formats scale — a structural shift worth tracking, since it moves margin toward specialty distributors and away from health-system pharmacy.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Share of 2025 Revenue (%) | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.4 | Antibody infusion capacity, registry analytics |
| Europe | 28.6 | HTA navigation, biosimilar readiness |
| Asia-Pacific | 22.1 | National screening, domestic manufacturing |
| South America | 5.4 | Public procurement, generic supply |
| Middle East & Africa | 4.5 | Specialist center build-out |
| Total | 100.0 | — |

Regional performance across the neurodegenerative disease market diverges sharply on reimbursement policy rather than disease burden. Burden is broadly proportional to the elderly population; revenue is not.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.6% share of region | Medicare registry coverage for antibodies |
| Canada | USD 1.97 billion (2025) | Provincial formulary expansion |
| Mexico | 8.4% CAGR (2026–2035) | IMSS neurology capacity investment |

Coverage policy is the whole story in the United States. CMS conditioned payment for amyloid-directed antibodies on enrollment in a qualifying registry, which preserved access while capping uncontrolled utilization. The result is a market that grew steadily rather than explosively. Canada's provinces move on separate timelines, with Ontario and Quebec typically leading. Mexico grows from a low base as specialist infrastructure expands.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 22.4% share of region | AMNOG pricing negotiations post-launch |
| UK | USD 2.64 billion (2025) | NICE appraisal outcomes on antibodies |
| France | 15.1% share of region | Centre Mémoire referral network |
| Italy | 7.2% CAGR (2026–2035) | AIFA innovative medicines fund |
| Spain | USD 1.37 billion (2025) | Regional health service procurement |
| Nordic Countries | 7.2% share of region | Registry-based outcomes tracking |
| Russia | 6.9% CAGR (2026–2035) | Domestic generic substitution |
| Rest of Europe | 11.1% share of region | Cross-border referral for specialist care |

Europe's regulators drew a narrower line than their US counterparts, restricting eligible populations for lecanemab and declining donanemab, which reshaped commercial expectations across the continent [[14]](https://ema.europa.eu). Germany's post-launch price negotiation compresses realizable revenue within twelve months of entry. The UK's appraisal process weighs cost-effectiveness against a threshold that modest cognitive benefit struggles to clear.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| Japan | 27.3% share of region | Early lecanemab approval and national coverage |
| China | 9.6% CAGR (2026–2035) | Provincial dementia screening programs |
| India | USD 0.62 billion (2025) | Generic manufacturing scale, rising diagnosis |
| South Korea | 9.8% share of region | National dementia responsibility policy |
| ASEAN | USD 0.71 billion (2025) | Urban private-pay neurology growth |
| Rest of Asia-Pacific | 8.2% CAGR (2026–2035) | Aging in Australia and Taiwan |

Japan moved faster than any other market outside the US, approving lecanemab in 2023 and folding it into national [health insurance](https://www.marketresearchfuture.com/reports/health-insurance-market-8227) shortly after — a function of both demographic urgency and Eisai's domestic origin. China's growth comes from diagnosis rather than premium therapy; provincial screening initiatives are surfacing patients who previously never entered the system. South Korea's national dementia policy funds community centers that perform the same triage function.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 54.2% share of region | SUS public procurement of symptomatic drugs |
| Argentina | USD 0.55 billion (2025) | Private insurance neurology coverage |
| Rest of South America | 8.0% CAGR (2026–2035) | Urban diagnostic capacity growth |

Brazil's unified health system procures symptomatic therapy at scale and low unit cost, which produces high volume and thin value. Premium therapies reach only private-insurance populations concentrated in São Paulo and Rio de Janeiro. Argentina's economic volatility complicates multi-year pricing agreements, pushing suppliers toward shorter contract cycles.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.4% share of region | Vision 2030 healthcare capacity investment |
| UAE | USD 0.48 billion (2025) | Medical tourism and specialist recruitment |
| South Africa | 21.6% share of region | Private hospital neurology networks |
| Egypt | 9.1% CAGR (2026–2035) | Public health insurance rollout |
| Rest of MEA | 18.5% share of region | Donor-funded chronic disease programs |

Gulf states are buying capability, not just product. Saudi Arabia's health transformation program funds tertiary neurology centers and imaging capacity that did not exist a decade ago, and the UAE recruits specialists into private networks serving regional patients. Sub-Saharan Africa remains diagnosis-limited; dementia is frequently recorded as normal aging rather than disease [[8]](https://who.int).

## Competitive Benchmarking

## Competitive Benchmarking

Average concentration. The top five players account for an estimated 46-52% of global revenue, with an approximate HHI in the 800-1,100 range - competitive by antitrust criteria, but concentrated within certain indications where one or two brands dominate. The trend is barbell shaped, with the big pharmas having the commercial infrastructure, the small biotechs having most of the genetically targeted pipeline, and licensing into the majors at Phase II.

| Company | Est. Revenue Share Range | Key Offerings for the Neurodegenerative Disease Market | Strategic Positioning |
| --- | --- | --- | --- |
| Biogen | ~11–14% | Lecanemab (with Eisai), MS portfolio, tofersen | Deepest Alzheimer's commercial infrastructure; MS base funds neurology R&D |
| Eisai | ~9–12% | Lecanemab origination, subcutaneous maintenance format | Discovery-side leader in amyloid; strong Japan position |
| Eli Lilly | ~8–11% | Donanemab, remternetug pipeline | Fast follower with monthly dosing and stop-treatment protocol |
| AbbVie | ~7–10% | Subcutaneous levodopa infusion, tavapadon, Cerevel assets | Parkinson's delivery leader after Cerevel acquisition |
| Roche / Genentech | ~6–9% | MS franchise, trontinemab, diagnostic assays | Only major with paired therapeutic and diagnostic capability |
| Novartis | ~5–8% | MS therapies, Huntington's collaboration assets | Building neuro pipeline through external partnerships |
| Teva | ~4–6% | Generic symptomatic portfolio, MS legacy | Volume supplier across emerging markets |
| Lundbeck | ~3–5% | Parkinson's and dementia-related psychiatry | Focused specialist with strong European footprint |
| UCB | ~2–4% | Alpha-synuclein and tau programs | Partnership-driven pipeline in synucleinopathies |
| Supernus Pharmaceuticals | ~1–3% | Wearable apomorphine infusion for motor fluctuations | Niche device-drug entrant in advanced Parkinson's |
| Denali Therapeutics | ~1–2% | Blood-brain barrier transport platform | Platform licensor for CNS delivery |
| uniQure | <1% | AAV gene therapy for Huntington's | Pure-play gene therapy developer |

## Recent News & Developments

## Recent News & Developments

- FDA (July 2023): Granted traditional approval to lecanemab following confirmatory Phase III data, establishing the first fully approved disease-modifying treatment for early Alzheimer's and opening the door to broad Medicare coverage [[1]](https://fda.gov).
- FDA / Eli Lilly (July 2024): Approved donanemab for early symptomatic Alzheimer's after a unanimous advisory committee vote, adding a monthly-infusion alternative with a defined treatment-stopping rule once amyloid clears [[3]](https://alzint.org).
- AbbVie (October 2024): Won FDA approval for subcutaneous foscarbidopa/foslevodopa for motor fluctuations in advanced Parkinson's after two prior complete response letters, creating the first 24-hour continuous levodopa infusion in the US [[5]](https://news.abbvie.com).
- uniQure (November 2024): Reached alignment with the FDA on key elements of an accelerated approval pathway for its Huntington's gene therapy, based on Phase I/II data against an external control arm [[11]](https://sec.gov).
- Supernus Pharmaceuticals (February 2025): Secured FDA approval for a wearable apomorphine infusion pump on its fourth attempt, launching in Q2 2025 with a dedicated nurse education program [[10]](https://supernus.com).

- FDA / Eisai and Biogen (August 2025): Approved a once-weekly subcutaneous autoinjector for lecanemab maintenance dosing after 18 months of intravenous initiation, enabling at-home administration [[4]](https://practicalneurology.com).
- uniQure (November–December 2025): Disclosed that FDA feedback at a pre-BLA meeting reversed prior guidance on whether Phase I/II external-control data could support a filing, leaving submission timing for its Huntington's gene therapy unclear despite positive 36-month pivotal results [[11]](https://sec.gov).

## Frequently Asked Questions

**Q: What should investors evaluating the neurodegenerative disease market watch beyond approval headlines?**
A: Watch infusion capacity and MRI throughput at treating centers. Approval creates eligibility; site capacity determines actual revenue timing, and most launch models have overestimated it [4].

**Q: How do buyers assess whether an antibody supplier can support a hospital contract?**
A: Ask for ARIA monitoring support, MRI scheduling assistance, and reimbursement navigation staffing. Product differentiation in this class is thin, so service wrap decides most institutional contracts [1][3].

**Q: Which competitive dynamic is most underestimated in the neurodegenerative disease market?**
A: Delivery format, not mechanism. A subcutaneous or monthly option can take share from a clinically equivalent biweekly infusion simply by freeing chair time and caregiver hours [4][5].

**Q: What regulatory nuance most often surprises companies entering Europe?**
A: Marketing authorization and funded access are separate hurdles. National HTA bodies can restrict eligible populations further than the EMA already has, adding 12–24 months before meaningful volume [14].

**Q: How reliable is external-control-arm evidence for rare neurodegenerative indications?**
A: Less reliable than sponsors assumed. Regulatory acceptance can shift mid-program, as one Huntington's gene therapy developer discovered when prior FDA alignment was reversed at the pre-BLA stage [11].

**Q: What integration challenge slows plasma biomarker testing adoption in primary care?**
A: Result interpretation. Positive amyloid status in a cognitively normal patient has no approved treatment pathway, so health systems need referral protocols before deploying screening broadly [6].

**Q: Which emerging use case could expand the neurodegenerative disease market fastest after 2030?**
A: Secondary prevention in asymptomatic biomarker-positive adults. A single positive readout would shift the category from specialist treatment to screened primary care.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218*